Physician profile
Eugene A Magee
NPI 1013014802
$2,225.75
in general payments reported to CMS, 2019-2025
14 companies · $289 in 2025
The $289 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $128 · 2021: $20.42 · 2022: $192 · 2023: $563 · 2024: $885 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,698 · Education: $39.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,697.67 |
| Education | $39.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $852.39 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Astrazeneca Pharmaceuticals LP | $364.20 | 2023-2025 | Farxiga, Lokelma |
| Amgen INC. | $254.66 | 2019-2024 | Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $218.48 | 2023-2025 | |
| Vifor Pharma, INC. | $133.97 | 2019-2024 | Veltassa, Korsuva |
| Ardelyx, INC. | $114.72 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $85.93 | 2023 | Jesduvroq |
| Mallinckrodt Enterprises LLC | $47.53 | 2019 | |
| Akebia Therapeutics INC | $47.10 | 2022-2024 | Vafseo |
| Lilly USA, LLC | $42.13 | 2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $27.99 | 2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.51 | 2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $12.75 | 2022 | |
| Travere Therapeutics, INC. | $0.39 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Magee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.